This episode delivers an in-depth analysis of recent European Union regulatory developments spanning Regulatory Oversight, Basel III financial standards, EUDAMED medical device regulation, European Parliament legislative activities, and cybersecurity challenges.

Among the critical updates, the European Medicines Agency’s CHMP endorsed marketing authorisation for Joenja under exceptional circumstances, emphasizing stringent physician oversight for treating activated phosphoinositide 3-kinase delta syndrome. Additionally, the EU medical device sector faces a significant regulatory milestone with mandatory use of key EUDAMED modules starting May 28, 2026, including registration deadlines for legacy and new devices designed to enhance transparency and market surveillance.

Cybersecurity concerns were highlighted in France’s CERTFR bulletin 2026-ACT-012, detailing critical vulnerabilities and a spike in phishing attacks targeting instant messaging accounts of political and administrative figures. Stakeholders are urged to apply vendor patches and monitor account devices vigilantly.

For more information, visit the Carver Agents website.

Articles mentioned:

1. Bulletin d'actualité CERTFR-2026-ACT-012 (23 mars 2026)
2. Basel III monitoring report
3. Chikungunya : l’ANSM poursuit la surveillance des effets indésirables du vaccin Ixchiq
4. Summary report on authorisation – Zepzelca®
5. Human medicines European public assessment report (EPAR): Joenja, leniolisib, Status: Opinion
6. Mandatory Use of EUDAMED modules for medical devices
7. 27/03/2026 - PCWP/HCPWP joint meeting
8. CM 2200 2026 INIT
9. Implementing Technical standards for uniform reporting under the Single Euro Payments Area Regulation
10. Human medicines European public assessment report (EPAR): Blarcamesine Anavex, blarcamesine, Status: Application withdrawn